BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Key Takeaways

  • Revenue reached $353.17 M, up from $120.70 M, and the company still lost $60.50 M in the quarter.
  • Of the quarter's $232.47 M sales rise, 32% came from one $75.0 M Bayer sales milestone.
  • Research, selling and overhead costs took $344.36 M, more than the $332.72 M gross profit.
  • Research spending fell to 40.6% of sales this quarter, from 93.5% a year earlier.

The Unvarnished Truth

BridgeBio's sales rose 193%, yet the quarter still lost money

BridgeBio's sales rose 193% this quarter, to $353.17 M, and the headline looks like a turnaround. Look under the total. Net product revenue reached $253.35 M, a real gain. The filing says the license line's rise came mainly from a $75.0 M sales milestone under the Bayer License Agreement. That one milestone was 32% of the quarter's $232.47 M rise in sales. Over nine months, license and services revenue actually fell 29%, from $125.44 M to $89.54 M. Without the milestone, the loss would have been about $135.50 M, all else equal.

Why does the loss survive a surge in sales? Research, selling and overhead costs took $344.36 M, more than the $332.72 M of gross profit left after direct costs. Management says the research increase is primarily driven by late-stage programs. The larger drag sits below the operating line, at $42.28 M of noncash interest on deferred royalty obligations, which the filing treats as debt owed to royalty purchasers. That charge is not paid in cash, so it widens the loss without draining the bank account.

What it means: the product line is the real engine, up 134% to $253.35 M, but it does not yet carry the whole cost base. The milestone was a single event, so the quarter's growth rate cannot be read as a run rate. Interest on its debt and royalty obligations ran $55.54 M in the quarter, on top of the operating loss. Nine months of product sales show the same pattern, with license income swinging while product revenue keeps climbing. Will product sales alone cover research, overhead and interest in a quarter with no milestone?

Revenue by Product and Service

Swipe to see the full flow
BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETNet product revenueLicense and services revenueRoyalty revenueTotal revenues, netGross profit (calculated)Total cost of revenuesLoss from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentLoss before income taxesTotal other expense, netNet lossProvision for (benefit from) income taxesGross profit (calculated)Gross profit(calculated)$332.72 MLoss before income taxesLoss beforeincome taxes−$59.27 MTotal revenues, netTotal revenues, net$353.17 MLoss from operationsLoss from operations−$11.64 MNet lossNet loss−$60.50 MOperating expenses (calculated)Operating expenses(calculated)$344.36 MNet product revenueNet product revenue$253.35 MProvision for (benefit from) income taxesProvision for (benefitfrom) income taxes$1.23 MSelling, general and administrativeSelling, general and administrative$200.85 MLicense and services revenueLicense and services revenue$79.31 MTotal cost of revenuesTotal cost of revenues$20.45 MRoyalty revenueRoyalty revenue$20.51 MResearch and developmentResearch and development$143.51 MTotal other expense, netTotal otherexpense, net−$47.63 M
Chart details

BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues, net
353,171,000 US dollars
Total cost of revenues
20,450,000 US dollars
Gross profit (calculated)
332,721,000 US dollars
Operating expenses (calculated)
344,360,000 US dollars
Loss from operations
negative 11,639,000 US dollars
Total other expense, net
negative 47,628,000 US dollars
Loss before income taxes
negative 59,267,000 US dollars
Provision for (benefit from) income taxes
1,229,000 US dollars
Net loss
negative 60,496,000 US dollars
Net product revenue
253,346,000 US dollars
License and services revenue
79,314,000 US dollars
Royalty revenue
20,511,000 US dollars
Restructuring, impairment, and related charges
0 US dollars
Research and development
143,506,000 US dollars
Selling, general and administrative
200,854,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.
BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement Sankey chart, Product and service view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Intelligent Insights for Investors

Did BridgeBio make a profit this period?

No. BridgeBio lost $60.50 M this quarter, or 17 cents of every sales dollar. Its operating result was a loss of $11.64 M, before interest and other items.

Do BridgeBio's numbers back up its explanation for its sales change?

Mostly. Net product revenue added $145.24 M of the $232.47 M rise in sales. The filing says the license line's rise came mainly from a $75.0 M sales milestone under the Bayer License Agreement.

Intelligent Insights for Lenders

Does BridgeBio earn enough to cover its interest payments?

No. Its operating result was a loss of $11.64 M this quarter, against $13.26 M of interest expense. A year earlier the operating loss was $145.20 M, against $11.74 M of interest.

Intelligent Insights for Employees

What is BridgeBio's biggest expense?

Selling, general and administrative expense is the largest, at $56.87 of every $100 of sales this quarter. Research and development comes second, at $40.63 of every $100.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!